vs

Side-by-side financial comparison of GENESIS ENERGY LP (GEL) and RAYONIER ADVANCED MATERIALS INC. (RYAM). Click either name above to swap in a different company.

GENESIS ENERGY LP is the larger business by last-quarter revenue ($440.8M vs $417.5M, roughly 1.1× RAYONIER ADVANCED MATERIALS INC.). GENESIS ENERGY LP runs the higher net margin — 4.5% vs -5.0%, a 9.6% gap on every dollar of revenue. On growth, GENESIS ENERGY LP posted the faster year-over-year revenue change (10.5% vs -1.2%). Over the past eight quarters, RAYONIER ADVANCED MATERIALS INC.'s revenue compounded faster (3.8% CAGR vs 0.7%).

Genesis Energy LP is a U.S.-based midstream energy limited partnership that operates critical infrastructure for crude oil, natural gas, refined petroleum products, and specialty industrial materials. Its core assets include pipelines, storage terminals, marine facilities, and rail logistics hubs, serving refineries, industrial clients, and energy distributors across North America.

Rayonier Advanced Materials recently rebranded as RYAM. RYAM is an American company recognized globally for its cellulose-based technologies. Specializing in high-purity cellulose specialties, RYAM produces natural polymers extensively used in manufacturing filters, food, pharmaceuticals, and various industrial applications. Additionally, the company produces products for the paper and packaging industries. The company is publicly traded on the New York Stock Exchange under the ticker symbol ...

GEL vs RYAM — Head-to-Head

Bigger by revenue
GEL
GEL
1.1× larger
GEL
$440.8M
$417.5M
RYAM
Growing faster (revenue YoY)
GEL
GEL
+11.7% gap
GEL
10.5%
-1.2%
RYAM
Higher net margin
GEL
GEL
9.6% more per $
GEL
4.5%
-5.0%
RYAM
Faster 2-yr revenue CAGR
RYAM
RYAM
Annualised
RYAM
3.8%
0.7%
GEL

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
GEL
GEL
RYAM
RYAM
Revenue
$440.8M
$417.5M
Net Profit
$19.9M
$-21.1M
Gross Margin
8.9%
Operating Margin
20.4%
2.6%
Net Margin
4.5%
-5.0%
Revenue YoY
10.5%
-1.2%
Net Profit YoY
140.2%
-31.9%
EPS (diluted)
$0.04
$-0.33

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
GEL
GEL
RYAM
RYAM
Q4 25
$440.8M
$417.5M
Q3 25
$414.0M
$352.8M
Q2 25
$377.3M
$340.0M
Q1 25
$398.3M
$356.0M
Q4 24
$398.9M
$422.5M
Q3 24
$397.3M
$401.1M
Q2 24
$430.2M
$419.0M
Q1 24
$434.4M
$387.7M
Net Profit
GEL
GEL
RYAM
RYAM
Q4 25
$19.9M
$-21.1M
Q3 25
$9.2M
$-4.5M
Q2 25
$-406.0K
$-363.2M
Q1 25
$-469.1M
$-32.0M
Q4 24
$-49.4M
$-16.0M
Q3 24
$-17.2M
$-32.6M
Q2 24
$-8.7M
$11.4M
Q1 24
$11.4M
$-1.6M
Gross Margin
GEL
GEL
RYAM
RYAM
Q4 25
8.9%
Q3 25
9.7%
Q2 25
7.0%
Q1 25
6.8%
Q4 24
8.7%
Q3 24
10.9%
Q2 24
11.5%
Q1 24
9.5%
Operating Margin
GEL
GEL
RYAM
RYAM
Q4 25
20.4%
2.6%
Q3 25
19.0%
2.8%
Q2 25
17.9%
-0.4%
Q1 25
5.5%
-4.2%
Q4 24
3.4%
2.6%
Q3 24
12.2%
-4.2%
Q2 24
11.6%
6.7%
Q1 24
13.4%
4.4%
Net Margin
GEL
GEL
RYAM
RYAM
Q4 25
4.5%
-5.0%
Q3 25
2.2%
-1.3%
Q2 25
-0.1%
-106.8%
Q1 25
-117.8%
-9.0%
Q4 24
-12.4%
-3.8%
Q3 24
-4.3%
-8.1%
Q2 24
-2.0%
2.7%
Q1 24
2.6%
-0.4%
EPS (diluted)
GEL
GEL
RYAM
RYAM
Q4 25
$0.04
$-0.33
Q3 25
$-0.05
$-0.07
Q2 25
$-0.12
$-5.44
Q1 25
$-4.06
$-0.49
Q4 24
$-0.58
$-0.25
Q3 24
$-0.32
$-0.49
Q2 24
$-0.25
$0.17
Q1 24
$-0.09
$-0.02

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
GEL
GEL
RYAM
RYAM
Cash + ST InvestmentsLiquidity on hand
$6.4M
$75.4M
Total DebtLower is stronger
$3.0B
$758.1M
Stockholders' EquityBook value
$316.6M
Total Assets
$4.9B
$1.8B
Debt / EquityLower = less leverage
2.39×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
GEL
GEL
RYAM
RYAM
Q4 25
$6.4M
$75.4M
Q3 25
$4.9M
$77.0M
Q2 25
$4.5M
$70.7M
Q1 25
$377.4M
$129.9M
Q4 24
$7.4M
$125.2M
Q3 24
$13.0M
$136.1M
Q2 24
$13.7M
$114.1M
Q1 24
$7.0M
$54.6M
Total Debt
GEL
GEL
RYAM
RYAM
Q4 25
$3.0B
$758.1M
Q3 25
$3.1B
$763.5M
Q2 25
$3.1B
$720.4M
Q1 25
$3.4B
$707.0M
Q4 24
$3.7B
$706.4M
Q3 24
$4.0B
$747.7M
Q2 24
$3.9B
$752.8M
Q1 24
$3.8B
$755.6M
Stockholders' Equity
GEL
GEL
RYAM
RYAM
Q4 25
$316.6M
Q3 25
$338.2M
Q2 25
$342.3M
Q1 25
$688.1M
Q4 24
$713.9M
Q3 24
$732.7M
Q2 24
$755.1M
Q1 24
$741.8M
Total Assets
GEL
GEL
RYAM
RYAM
Q4 25
$4.9B
$1.8B
Q3 25
$4.9B
$1.8B
Q2 25
$4.8B
$1.8B
Q1 25
$5.2B
$2.1B
Q4 24
$7.0B
$2.1B
Q3 24
$7.1B
$2.2B
Q2 24
$7.0B
$2.2B
Q1 24
$6.9B
$2.1B
Debt / Equity
GEL
GEL
RYAM
RYAM
Q4 25
2.39×
Q3 25
2.26×
Q2 25
2.10×
Q1 25
1.03×
Q4 24
0.99×
Q3 24
1.02×
Q2 24
1.00×
Q1 24
1.02×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
GEL
GEL
RYAM
RYAM
Operating Cash FlowLast quarter
$110.8M
$32.3M
Free Cash FlowOCF − Capex
$87.0M
FCF MarginFCF / Revenue
19.7%
Capex IntensityCapex / Revenue
5.4%
Cash ConversionOCF / Net Profit
5.58×
TTM Free Cash FlowTrailing 4 quarters
$65.9M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
GEL
GEL
RYAM
RYAM
Q4 25
$110.8M
$32.3M
Q3 25
$70.3M
$-17.8M
Q2 25
$47.0M
$-30.2M
Q1 25
$24.8M
$39.6M
Q4 24
$74.0M
$54.9M
Q3 24
$87.3M
$49.8M
Q2 24
$104.7M
$87.6M
Q1 24
$125.9M
$11.3M
Free Cash Flow
GEL
GEL
RYAM
RYAM
Q4 25
$87.0M
Q3 25
$43.3M
Q2 25
$-7.6M
Q1 25
$-56.8M
Q4 24
$-47.1M
Q3 24
$-32.3M
Q2 24
$-67.5M
Q1 24
$-48.3M
FCF Margin
GEL
GEL
RYAM
RYAM
Q4 25
19.7%
Q3 25
10.5%
Q2 25
-2.0%
Q1 25
-14.3%
Q4 24
-11.8%
Q3 24
-8.1%
Q2 24
-15.7%
Q1 24
-11.1%
Capex Intensity
GEL
GEL
RYAM
RYAM
Q4 25
5.4%
Q3 25
6.5%
Q2 25
14.5%
Q1 25
20.5%
Q4 24
30.3%
Q3 24
30.1%
Q2 24
40.0%
Q1 24
40.1%
Cash Conversion
GEL
GEL
RYAM
RYAM
Q4 25
5.58×
Q3 25
7.63×
Q2 25
Q1 25
Q4 24
Q3 24
Q2 24
7.69×
Q1 24
11.09×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

GEL
GEL

Onshore Facilities And Transportation Revenue$204.2M46%
Offshore Pipeline Transportation Revenue$154.3M35%
Marine Transportation Revenue$82.2M19%

RYAM
RYAM

Cellulose Specialties$249.6M60%
Other$86.2M21%
Paperboard$44.2M11%
High Yield Pulp$28.3M7%
Biomaterials$9.2M2%

Related Comparisons